Cargando…
Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials
BACKGROUND: The phase II J003 (N = 169) and phase III RECOURSE (N = 800) trials demonstrated a significant improvement in survival with trifluridine (FTD)/tipiracil (TPI) versus placebo in patients with refractory metastatic colorectal cancer. This post hoc analysis investigated pharmacokinetic data...
Autores principales: | Yoshino, T., Cleary, J. M., Van Cutsem, E., Mayer, R. J., Ohtsu, A., Shinozaki, E., Falcone, A., Yamazaki, K., Nishina, T., Garcia-Carbonero, R., Komatsu, Y., Baba, H., Argilés, G., Tsuji, A., Sobrero, A., Yamaguchi, K., Peeters, M., Muro, K., Zaniboni, A., Sugimoto, N., Shimada, Y., Tsuji, Y., Hochster, H. S., Moriwaki, T., Tran, B., Esaki, T., Hamada, C., Tanase, T., Benedetti, F., Makris, L., Yamashita, F., Lenz, H.-J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491979/ https://www.ncbi.nlm.nih.gov/pubmed/31912801 http://dx.doi.org/10.1016/j.annonc.2019.10.005 |
Ejemplares similares
-
Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis
por: Tabernero, Josep, et al.
Publicado: (2020) -
QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer
por: Tabernero, Josep, et al.
Publicado: (2017) -
The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer
por: Van Cutsem, Eric, et al.
Publicado: (2017) -
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer
por: Van Cutsem, E., et al.
Publicado: (2022) -
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial
por: Longo-Muñoz, F., et al.
Publicado: (2016)